Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq Other stock markets 01:30:02 02/05/2024 am IST			5-day change	1st Jan Change
38.8 ^USD	+4.09%		+9.03%	+35.30%

12/04	Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	MT
12/04	Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	12/04	MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	12/04	MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target	11/03	MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating	08/03	MT
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating	27/02	MT
Wedbush Starts Revolution Medicines With Outperform Rating, $41 Price Target	04/01	MT
UBS Initiates Coverage on Revolution Medicines With Buy Rating, $40 Price Target	20/12	MT
Raymond James Starts Revolution Medicines With Outperform Rating, Price Target is $30	16/11	MT
Oppenheimer Raises Revolution Medicines Price Target to $43 From $40, Maintains Outperform Rating	23/23/23	MT
Needham Adjusts Revolution Medicines Price Target to $36 From $34, Maintains Buy Rating	23/23/23	MT
Stifel Raises Revolution Medicines' Price Target to $47 From $37, Keeps Buy Rating	21/23/21	MT
Needham Adjusts Price Target on Revolution Medicines to $34 From $35, Maintains Buy Rating	09/23/09	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $40 From $35, Maintains Outperform Rating	02/23/02	MT
Needham Adjusts Price Target on Revolution Medicines to $35 From $31, Maintains Buy Rating	02/23/02	MT
Needham Adjusts Price Target on Revolution Medicines to $32 From $34, Maintains Buy Rating	09/23/09	MT
Goldman Sachs Adjusts Price Target on Revolution Medicines to $23 From $20, Maintains Neutral Rating	01/23/01	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $35 From $30, Maintains Outperform Rating	28/23/28	MT
Needham Adjusts Revolution Medicines' Price Target to $38 From $32, Maintains Buy Rating	28/23/28	MT
JPMorgan Upgrades Revolution Medicines to Overweight From Neutral, Boosts Price Target to $38 From $32	28/23/28	MT
Needham Initiates Revolution Medicines at Buy Rating With $31 Price Target	14/22/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Analyst Reco.

Filters